Talphera (TLPH) Competitors $0.53 +0.02 (+3.60%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. XFOR, SCLX, OSTX, NRXP, SRZN, ATHE, CVKD, PLUR, MRNS, and KZRShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include X4 Pharmaceuticals (XFOR), Scilex (SCLX), OS Therapies (OSTX), NRx Pharmaceuticals (NRXP), Surrozen (SRZN), Alterity Therapeutics (ATHE), Cadrenal Therapeutics (CVKD), Pluri (PLUR), Marinus Pharmaceuticals (MRNS), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Talphera vs. X4 Pharmaceuticals Scilex OS Therapies NRx Pharmaceuticals Surrozen Alterity Therapeutics Cadrenal Therapeutics Pluri Marinus Pharmaceuticals Kezar Life Sciences X4 Pharmaceuticals (NASDAQ:XFOR) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation. Do insiders & institutionals have more ownership in XFOR or TLPH? 72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 1.6% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, XFOR or TLPH? Talphera has lower revenue, but higher earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX4 Pharmaceuticals$2.56M254.69-$101.17M-$0.19-19.74Talphera$281K31.13-$18.40M-$0.51-1.00 Does the MarketBeat Community favor XFOR or TLPH? X4 Pharmaceuticals received 69 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 68.10% of users gave X4 Pharmaceuticals an outperform vote. CompanyUnderperformOutperformX4 PharmaceuticalsOutperform Votes7968.10% Underperform Votes3731.90% TalpheraOutperform Votes10100.00% Underperform VotesNo Votes Does the media refer more to XFOR or TLPH? In the previous week, X4 Pharmaceuticals had 12 more articles in the media than Talphera. MarketBeat recorded 14 mentions for X4 Pharmaceuticals and 2 mentions for Talphera. Talphera's average media sentiment score of 0.44 beat X4 Pharmaceuticals' score of -0.06 indicating that Talphera is being referred to more favorably in the news media. Company Overall Sentiment X4 Pharmaceuticals Neutral Talphera Neutral Is XFOR or TLPH more profitable? Talphera's return on equity of -118.46% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets X4 PharmaceuticalsN/A -236.19% -75.14% Talphera N/A -118.46%-65.82% Do analysts prefer XFOR or TLPH? X4 Pharmaceuticals presently has a consensus price target of $85.00, suggesting a potential upside of 2,166.67%. Talphera has a consensus price target of $4.33, suggesting a potential upside of 747.02%. Given X4 Pharmaceuticals' higher probable upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than Talphera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Talphera 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Which has more volatility & risk, XFOR or TLPH? X4 Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. SummaryX4 Pharmaceuticals and Talphera tied by winning 9 of the 18 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.38M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.747.3222.5118.54Price / Sales31.13241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.626.486.734.25Net Income-$18.40M$143.41M$3.22B$248.18M7 Day Performance5.27%2.58%1.38%1.03%1 Month Performance-12.25%5.00%2.79%2.70%1 Year Performance-50.33%-3.72%15.41%4.05% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera2.268 of 5 stars$0.53+3.6%$4.33+717.6%-48.8%$9.06M$281,000.00-0.7719Gap UpXFORX4 Pharmaceuticals3.9617 of 5 stars$0.19-1.0%$2.83+1,399.9%-88.7%$32.81M$2.56M-2.1080Analyst ForecastStock SplitNews CoverageGap DownSCLXScilex2.9568 of 5 stars$4.70-21.9%$455.00+9,580.9%-83.0%$32.71M$56.59M-5.6680High Trading VolumeOSTXOS Therapies1.9687 of 5 stars$1.49-2.6%$18.00+1,108.1%N/A$32.28MN/A0.00N/AGap DownNRXPNRx Pharmaceuticals2.3526 of 5 stars$1.87-3.1%$28.25+1,410.7%-4.6%$31.63MN/A-0.872Analyst ForecastNews CoverageGap DownSRZNSurrozen3.9205 of 5 stars$9.60-1.5%$38.50+301.0%+7.0%$31.50M$10.66M-0.4480Short Interest ↓Positive NewsATHEAlterity Therapeutics1.9719 of 5 stars$3.45-1.4%$12.00+247.8%+55.0%$30.59MN/A0.0010Short Interest ↑News CoverageGap UpCVKDCadrenal Therapeutics3.2801 of 5 stars$16.18-3.4%$32.00+97.8%N/A$30.42MN/A-2.424Upcoming EarningsShort Interest ↓News CoveragePLURPluri0.593 of 5 stars$4.34+7.7%N/A-8.9%$30.37M$678,000.00-0.77150Upcoming EarningsHigh Trading VolumeMRNSMarinus Pharmaceuticals1.9441 of 5 stars$0.55-0.2%$4.79+771.6%-62.6%$30.32M$30.99M-0.22110Upcoming EarningsKZRKezar Life Sciences4.0372 of 5 stars$4.15-0.2%$39.50+851.8%-47.5%$30.32M$7M-0.3160Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies X4 Pharmaceuticals Alternatives Scilex Alternatives OS Therapies Alternatives NRx Pharmaceuticals Alternatives Surrozen Alternatives Alterity Therapeutics Alternatives Cadrenal Therapeutics Alternatives Pluri Alternatives Marinus Pharmaceuticals Alternatives Kezar Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
